Trials / Completed
CompletedNCT00150592
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
A Phase II Study to Assess the Safety, Tolerability and Efficacy of SPD503 Administered to Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 182 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPD503 (Guanfacine HCl) | |
| DRUG | Placebo |
Timeline
- Start date
- 2005-05-12
- Primary completion
- 2005-10-05
- Completion
- 2005-10-05
- First posted
- 2005-09-08
- Last updated
- 2021-06-10
- Results posted
- 2009-10-14
Source: ClinicalTrials.gov record NCT00150592. Inclusion in this directory is not an endorsement.